Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 30, 2026 16:05 ET | Source: AEON Biopharma Inc

AEON Biopharma Reports Full Year 2025 Financial Results and Highlights Positive Comparative Analytical Results and FDA Feedback for ABP-450 Biosimilar Program

AEON Biopharma Reports Full Year 2025 Financial Results and Highlights Positive Comparative Analytical Results and FDA Feedback for ABP-450 Biosimilar Prog
March 30, 2026 08:00 ET | Source: Teva Pharmaceutical Industries Ltd

Teva Gains Biosimilar Momentum with U.S. FDA Approval of PONLIMSI™ (denosumab-adet) and Dual Filing Acceptance for Biosimilar Candidate to Xolair® (omalizumab)

Teva’s biosimilar, PONLIMSI™, is now FDA-approved across all indications of the reference product, Prolia® (denosumab), to treat a variety of debilitating bone conditions.Teva’s proposed biosimilar...
March 25, 2026 08:00 ET | Source: AEON Biopharma Inc

AEON Biopharma Announces FDA Feedback Following BPD Type 2a Meeting for the ABP-450 Biosimilar Program

AEON Biopharma Announces FDA Feedback Following BPD Type 2a Meeting for the ABP-450 Biosimilar Program
March 05, 2026 16:05 ET | Source: AEON Biopharma Inc

AEON Biopharma Abstract Accepted for Presentation at 2026 American Academy of Neurology (AAN) Annual Meeting

AEON Biopharma Abstract Accepted for Presentation at 2026 American Academy of Neurology (AAN) Annual Meeting
February 27, 2026 10:52 ET | Source: Research and Markets

Generic and Biosimilar Pharmaceuticals Industry Report 2026, Individual Assessment of the Largest 1,120 Companies with the Top 50 Ranked by Market Share, Sales Growth, Gross Profit and Pre-tax Profit

Dublin, Feb. 27, 2026 (GLOBE NEWSWIRE) -- The "Generic and Biosimilar Pharmaceuticals - Industry Report" report has been added to ResearchAndMarkets.com's offering. Using an exclusive...